应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ALMR Alamar Biosciences, Inc.
休市中 10-23 16:00:00 EDT
30.69
+0.97
+3.26%
盘后
30.63
-0.06
-0.20%
19:42 EDT
最高
31.46
最低
28.61
成交量
74.82万
今开
29.65
昨收
29.72
日振幅
9.61%
总市值
21.27亿
流通市值
12.09亿
总股本
6,931万
成交额
2,293万
换手率
1.90%
流通股本
3,938万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Alamar Biosciences携手阿尔茨海默病数据倡议与Gates Ventures,深化全球合作
美股速递 · 08-11
Alamar Biosciences携手阿尔茨海默病数据倡议与Gates Ventures,深化全球合作
财报前瞻|Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元,机构观点偏看多
财报Agent · 08-03
财报前瞻|Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元,机构观点偏看多
Alzpath 扩大与 Alamar Biosciences 的战略合作,推动阿尔茨海默病临床诊断进步
美股速递 · 07-23
Alzpath 扩大与 Alamar Biosciences 的战略合作,推动阿尔茨海默病临床诊断进步
Alamar Biosciences推出首个基于血液的Emtbr-tau多重免疫检测方法,该标志物为阿尔茨海默病研究最重要生物标志物之一
美股速递 · 07-07
Alamar Biosciences推出首个基于血液的Emtbr-tau多重免疫检测方法,该标志物为阿尔茨海默病研究最重要生物标志物之一
美银全球研究开始覆盖Alamar Biosciences,给予中性评级及27美元目标价
美股速递 · 05-12
美银全球研究开始覆盖Alamar Biosciences,给予中性评级及27美元目标价
Leerink Partners首予Alamar Biosciences“跑赢大盘”评级,目标价35美元
美股速递 · 05-12
Leerink Partners首予Alamar Biosciences“跑赢大盘”评级,目标价35美元
加载更多
公司概况
公司名称:
Alamar Biosciences, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Alamar Biosciences, Inc.于2018年5月7日在特拉华州注册成立,总部位于加利福尼亚州弗里蒙特市。该公司是一家商业化阶段的蛋白质组学公司,致力于建立蛋白质检测和分析的黄金标准。公司提供专有的NULISA平台,该平台能够以超高灵敏度、高特异性、灵活的多重检测、宽动态范围和自动化,检测非侵入性生物体液中的低丰度蛋白质生物标志物,从而实现“精准蛋白质组学”。公司提供仪器、耗材和分析软件的集成解决方案,用于发现、转化研究和诊断开发。
发行价格:
--
{"stockData":{"symbol":"ALMR","market":"US","secType":"STK","nameCN":"Alamar Biosciences, Inc.","latestPrice":30.69,"timestamp":1792785600000,"preClose":29.72,"halted":0,"volume":748226,"hourTrading":{"tag":"盘后","latestPrice":30.63,"preClose":30.69,"latestTime":"19:42 EDT","volume":3385,"amount":103879.65,"timestamp":1792798976802,"change":-0.06,"changeRate":-0.001955,"amplitude":0.001955},"delay":0,"changeRate":0.032637954239569396,"floatShares":39381524,"shares":69311200,"eps":-0.716,"marketStatus":"休市中","change":0.97,"latestTime":"10-23 16:00:00 EDT","open":29.65,"high":31.46,"low":28.605,"amount":22929722.4717,"amplitude":0.096063,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.716,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":29.72,"postHourTrading":{"tag":"盘后","latestPrice":30.63,"preClose":30.69,"latestTime":"19:42 EDT","volume":3385,"amount":103879.65,"timestamp":1792798976802,"change":-0.06,"changeRate":-0.001955,"amplitude":0.001955},"volumeRatio":1.067262},"requestUrl":"/m/hq/s/ALMR","defaultTab":"news","newsList":[{"id":"1165363440","title":"Alamar Biosciences携手阿尔茨海默病数据倡议与Gates Ventures,深化全球合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1165363440","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165363440?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:05","pubTimestamp":1786392312,"startTime":"0","endTime":"0","summary":"Alamar Biosciences(简称:ALMR)正积极拓展其全球战略版图,与阿尔茨海默病数据倡议(Alzheimer’s Disease Data Initiative)以及Gates Ventures达成更广泛的合作伙伴关系。这一举措,旨在通过数据共享与技术协同,加速对阿尔茨海默病的研究与疗法开发。合作方将整合各自资源,推动全球范围内的疾病数据整合与创新诊断工具的应用。Alamar Biosciences的管理层表示,此合作将进一步提升其平台在神经退行性疾病领域的应用潜力,为患者群体带来更精准的诊断方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130899284","title":"财报前瞻|Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元,机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1130899284","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130899284?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:55","pubTimestamp":1785718537,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.将于2026年08月10日盘后发布2026年第二季度财报,市场聚焦收入延续性与亏损收窄节奏。市场一致预期显示,本季度Alamar Biosciences, Inc.营收预计为2,593.98万美元,同比增速记录为0.00%;调整后每股收益预计为—0.33美元,同比增速记录为0.00%,公司层面暂未披露本季度的毛利率与净利率指引,亦未提供本季度收入指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元,机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120675244","title":"Alzpath 扩大与 Alamar Biosciences 的战略合作,推动阿尔茨海默病临床诊断进步","url":"https://stock-news.laohu8.com/highlight/detail?id=1120675244","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120675244?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:35","pubTimestamp":1784810143,"startTime":"0","endTime":"0","summary":"Alzpath 宣布,已进一步扩展与 Alamar Biosciences 的战略合作协议。双方旨在携手推进阿尔茨海默病的临床诊断技术。通过此次深化合作,Alzpath 将充分利用 Alamar Biosciences 的创新平台,加速相关诊断工具的开发与应用。这一举措有望为阿尔茨海默病的早期检测与精准诊断带来显著突破,从而更好地满足患者和医疗系统的迫切需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111524499","title":"Alamar Biosciences推出首个基于血液的Emtbr-tau多重免疫检测方法,该标志物为阿尔茨海默病研究最重要生物标志物之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1111524499","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111524499?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:16","pubTimestamp":1783430177,"startTime":"0","endTime":"0","summary":"Alamar Biosciences推出了首个基于血液的Emtbr-tau多重免疫检测方法。Emtbr-tau是阿尔茨海默病研究领域最为关键的生物标志物之一。这一创新检测方案的问世,标志着在利用血液样本进行神经退行性疾病精准诊断方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180385750","title":"美银全球研究开始覆盖Alamar Biosciences,给予中性评级及27美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180385750","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180385750?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:51","pubTimestamp":1778586675,"startTime":"0","endTime":"0","summary":"美银全球研究(BofA Global Research)已开始对生物科技公司Alamar Biosciences进行跟踪研究,并在其首份报告中给予该公司“中性”评级。与此同时,分析师为该股设定了27美元的目标价位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147513482","title":"Leerink Partners首予Alamar Biosciences“跑赢大盘”评级,目标价35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147513482","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147513482?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:07","pubTimestamp":1778580462,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布,首次覆盖生物科技公司Alamar Biosciences,并给予其“跑赢大盘”的评级。该机构为该公司设定了35美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alamarbio.com","stockEarnings":[{"period":"1week","weight":0.214},{"period":"1month","weight":-0.0451},{"period":"3month","weight":0.1859},{"period":"6month","weight":0.2355},{"period":"1year","weight":0.8053},{"period":"ytd","weight":0.8053}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alamar Biosciences, Inc.于2018年5月7日在特拉华州注册成立,总部位于加利福尼亚州弗里蒙特市。该公司是一家商业化阶段的蛋白质组学公司,致力于建立蛋白质检测和分析的黄金标准。公司提供专有的NULISA平台,该平台能够以超高灵敏度、高特异性、灵活的多重检测、宽动态范围和自动化,检测非侵入性生物体液中的低丰度蛋白质生物标志物,从而实现“精准蛋白质组学”。公司提供仪器、耗材和分析软件的集成解决方案,用于发现、转化研究和诊断开发。","exchange":"NASDAQ","name":"Alamar Biosciences, Inc.","nameEN":"Alamar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alamar Biosciences, Inc.(ALMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alamar Biosciences, Inc.(ALMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alamar Biosciences, Inc.,ALMR,Alamar Biosciences, Inc.股票,Alamar Biosciences, Inc.股票老虎,Alamar Biosciences, Inc.股票老虎国际,Alamar Biosciences, Inc.行情,Alamar Biosciences, Inc.股票行情,Alamar Biosciences, Inc.股价,Alamar Biosciences, Inc.股市,Alamar Biosciences, Inc.股票价格,Alamar Biosciences, Inc.股票交易,Alamar Biosciences, Inc.股票购买,Alamar Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alamar Biosciences, Inc.(ALMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alamar Biosciences, Inc.(ALMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}